Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMH0ZJE)

Drug Name
Mitomycin Drug Info
Synonyms
Mitomycin C; mitomycin C; 1950/7/7; Mutamycin; Ametycine; Mitocin-C; Ametycin; Mitomycin-C; Mytozytrex; Mitomycinum; Mytomycin; Mitozytrex; Mitomycinum C; Mitocin C; Mitomycins; Mitamycin; MMC; Mitosol; Mitomycyna C; 7-Amino-9alpha-methoxymitosane; NSC-26980; Mitomycyna C [Polish]; Mito-C; Mit-C; Mitomycin (TN); Mitomycinum [INN-Latin]; Mitomycine [INN-French]; Mitomicina [INN-Spanish]; NCI-C04706; RCRA waste number U010; NSC26980; NSC 26980; Mitomycine; CCRIS 414; UNII-50SG953SK6; HSDB 3239; C15H18N4O5; EINECS 200-008-6; Mitomycin C,; Ametycin; Mitomicina; Muamycin; Mitomycin C from Streptomyces caespitosus; Mitomycin C (JP15); Mitomycin C, Streptomyces caespitosus; Muamycin (TN); Mitomycin (USP/INN); Mitomycin [USAN:INN:BAN]; Mitomycin C, Streptomyces caespitosus, Carrier-Free
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
5746
ChEBI ID
CHEMBL27504
CAS Number
CAS 50-07-7
TTD Drug ID
D0Y0GH
VARIDT Drug ID
DR01212
ACDINA Drug ID
D01255

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
p53 signaling pathway 2.15 6.05e-3 63/73 (86.3%) SESN1;SERPINE1;PMAIP1;...
DNA replication 2.09 3.02e-3 34/36 (94.44%) PCNA;FEN1;POLE3;...
Base excision repair 2.04 2.02e-3 29/33 (87.88%) PCNA;PARP2;FEN1;...
Other glycan degradation 1.97 7.56e-3 13/18 (72.22%) FUCA1;NEU1;ENGASE;...
Ribosome 1.88 1.21e-2 113/158 (71.52%) RPL10;MRPS16;RPL36;...
Glutathione metabolism 1.79 1.61e-2 43/57 (75.44%) GSTT1;CHAC1;GPX1;...
Nucleotide excision repair 1.79 1.47e-2 40/47 (85.11%) PCNA;DDB2;GTF2H5;...
Autoimmune thyroid disease 1.78 1.59e-2 46/53 (86.79%) FAS;HLA-B;HLA-F;...
Type I diabetes mellitus 1.78 1.41e-2 38/43 (88.37%) FAS;HLA-B;HLA-F;...
Fanconi anemia pathway 1.75 1.75e-2 36/54 (66.67%) RAD51C;FANCL;POLI;...
Mismatch repair 1.71 2.20e-2 22/23 (95.65%) PCNA;RFC4;LIG1;...
Ribosome biogenesis in eukaryotes 1.69 2.62e-2 52/108 (48.15%) NOP56;NXT1;GNL3;...
Allograft rejection 1.67 2.65e-2 32/38 (84.21%) FAS;HLA-B;HLA-F;...
Graft-versus-host disease 1.65 2.85e-2 32/42 (76.19%) FAS;HLA-B;HLA-F;...
RNA polymerase 1.59 5.00e-2 23/31 (74.19%) POLR2H;POLR2F;POLR1B;...
Proteoglycans in cancer -1.64 3.70e-2 172/205 (83.9%) PLAUR;RAF1;ARAF;...
TGF-beta signaling pathway -1.68 2.50e-2 81/94 (86.17%) SP1;SMAD6;E2F5;...
Fc epsilon RI signaling pathway -1.69 2.54e-2 57/68 (83.82%) MAPK8;RAC2;IL13;...
Wnt signaling pathway -1.70 2.44e-2 124/166 (74.7%) CSNK2A1;EP300;PPP3CC;...
MicroRNAs in cancer -1.71 2.48e-2 146/310 (47.1%) ITGB3;PLCG1;EFNA1;...
AGE-RAGE signaling pathway in diabetic complications -1.72 2.19e-2 97/100 (97%) SMAD3;PLCG1;NOX1;...
Non-small cell lung cancer -1.72 2.06e-2 70/72 (97.22%) PLCG1;AKT2;AKT3;...
Acute myeloid leukemia -1.73 1.79e-2 66/67 (98.51%) PIK3CD;STAT5B;STAT3;...
Breast cancer -1.74 1.74e-2 119/147 (80.95%) AKT2;AKT3;SOS1;...
Relaxin signaling pathway -1.74 1.83e-2 114/129 (88.37%) ADCY2;ARRB1;CREB3L1;...
Amoebiasis -1.75 1.78e-2 99/102 (97.06%) CD1E;RELA;LAMC3;...
Prostate cancer -1.76 1.51e-2 93/97 (95.88%) AKT2;AKT3;SOS1;...
Hepatocellular carcinoma -1.78 1.29e-2 135/168 (80.36%) SMARCE1;SMAD3;PLCG1;...
Melanogenesis -1.79 1.29e-2 74/101 (73.27%) FZD10;FZD7;PLCB4;...
Parathyroid hormone synthesis, secretion and action -1.79 1.28e-2 98/106 (92.45%) GNA12;KL;LRP6;...
Focal adhesion -1.80 1.19e-2 180/201 (89.55%) PDGFRB;ITGA10;RAF1;...
Signaling pathways regulating pluripotency of stem cell... -1.80 1.08e-2 110/143 (76.92%) INHBA;HAND1;SMAD3;...
VEGF signaling pathway -1.80 1.16e-2 50/59 (84.75%) PIK3CD;PPP3CC;PRKCG;...
Cushing syndrome -1.81 1.14e-2 125/155 (80.65%) FZD10;FZD7;PLCB4;...
Oocyte meiosis -1.83 1.12e-2 90/129 (69.77%) ITPR1;PPP2R1A;CALML5;...
Carbohydrate digestion and absorption -1.83 1.10e-2 37/47 (78.72%) SLC2A2;G6PC3;CACNA1D;...
Transcriptional misregulation in cancer -1.84 1.22e-2 158/192 (82.29%) MLLT3;CEBPE;MLLT1;...
Thyroid hormone signaling pathway -1.84 1.37e-2 112/121 (92.56%) HIF1A;ACTB;KAT2B;...
Neurotrophin signaling pathway -1.87 1.37e-2 107/119 (89.92%) TP73;RPS6KA6;MAPK8;...
Sphingolipid signaling pathway -1.87 1.60e-2 106/119 (89.08%) MAPK8;RAC2;PPP2R2B;...
Platelet activation -1.95 5.48e-3 106/124 (85.48%) F2;ADCY2;FCGR2A;...
Progesterone-mediated oocyte maturation -2.01 6.85e-3 75/100 (75%) FZR1;PIK3CD;PKMYT1;...
AMPK signaling pathway -2.09 0.00e+0 106/120 (88.33%) PPARGC1A;EEF2;PPP2R2B;...
Leukocyte transendothelial migration -2.19 0.00e+0 90/114 (78.95%) PTPN11;CLDN5;ACTB;...
Adherens junction -2.34 0.00e+0 63/71 (88.73%) FYN;CTNNA2;PTPRM;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 0.12uM - 10uM 24H
TC-32 CVCL_7141 Homo sapiens 0.12uM - 1.11uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Brain
Glioblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-251 MG CVCL_0021 Homo sapiens 0.12uM - 10uM 24H
YH-13 CVCL_1800 Homo sapiens 0.12uM - 10uM 24H
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 0.12uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 0.12uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-474 CVCL_0179 Homo sapiens 0.12uM - 10uM 24H
T-47D CVCL_0553 Homo sapiens 0.12uM - 10uM 24H
ZR-75-1 CVCL_0588 Homo sapiens 0.12uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GP2d CVCL_1234 Homo sapiens 0.12uM - 1.11uM 24H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 0.12uM - 10uM 24H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WA09 (H9) Derived CVCL_9773 (WA09) Homo sapiens 0.12uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-151 CVCL_2927 Homo sapiens 0.12uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 0.12uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 0.12uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 0.12uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Renal cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RCC10RGB CVCL_1656 Homo sapiens 0.12uM - 10uM 24H
Rhabdoid tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
G-401 CVCL_0270 Homo sapiens 0.12uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 0.12uM - 10uM 24H
JHH-7 CVCL_1322 Homo sapiens 0.12uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
NCI-H1437 CVCL_1472 Homo sapiens 0.12uM - 1.11uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 0.12uM - 1.11uM 24H
NCI-H838 CVCL_1594 Homo sapiens 0.12uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 0.12uM - 10uM 24H
HCC1588 CVCL_1263 Homo sapiens 0.12uM - 1.11uM 24H
HCC95 CVCL_1276 Homo sapiens 0.12uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2110 CVCL_1529 Homo sapiens 0.12uM - 10uM 24H
NCI-H2172 CVCL_1534 Homo sapiens 0.12uM - 10uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H841 CVCL_1595 Homo sapiens 0.12uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 0.12uM - 10uM 24H
Oral cavity
Oral squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BICR 6 CVCL_1086 Homo sapiens 0.12uM - 10uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVK18 CVCL_1629 Homo sapiens 0.12uM - 10uM 24H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ES-2 CVCL_3509 Homo sapiens 1.11uM - 10uM 24H
OVTOKO CVCL_3114 Homo sapiens 0.12uM - 10uM 24H
Ovarian cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OAW 28 CVCL_1611 Homo sapiens 0.12uM - 10uM 24H
OC 316 CVCL_1615 Homo sapiens 0.12uM - 10uM 24H
Ovarian endometrioid carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TOV-112D CVCL_3612 Homo sapiens 0.12uM - 10uM 24H
Ovarian granulosa cell tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV434 CVCL_2010 Homo sapiens 0.12uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 0.12uM - 10uM 24H
LNCaP clone FGC CVCL_1379 Homo sapiens 0.12uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 0.12uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 0.12uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 0.12uM - 10uM 24H
SK-MEL-3 CVCL_0525 Homo sapiens 0.12uM - 10uM 24H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.12uM - 10uM 24H
MKN45 CVCL_0434 Homo sapiens 0.12uM - 10uM 24H
Gastric carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IM95 CVCL_1305 Homo sapiens 0.12uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 0.12uM - 1.11uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 0.12uM - 10uM 24H